Assembly Biosciences’ Bjorkquist sells shares for taxes

The reported stock sales funded tax withholding under a committee rule, and the award vests only with continuous service.

Available on EDGAR 11/03/2026 - 04:50 PM EST Accepted by SEC EDGAR 11/03/2026 - 04:50 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Assembly Biosciences, Inc. (ASMB) PFO and PAO Jeanette M. Bjorkquist reported acquisition of 3,840 shares under a performance-based restricted stock unit award on October 30, 2026, when its performance condition was achieved. The shares vest in two equal installments, assuming continuous service, on October 30, 2026 and October 30, 2027. On November 2, 2026, she sold 718 shares at a weighted average price of $19.6077 and 9 shares at $20.3480 to cover tax withholding under the Compensation Committee’s mandatory sell-to-cover rule; the sales were not discretionary. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Seller: 727 shares

Net Sell 3 txns

Insider Bjorkquist Jeanette M

Role PFO and PAO

Sold 727 shs ($14K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F2, F3}	718	$19.6077	$14K
Sale	Common Stock ^{F2, F4}	9	$20.348	$183.13
Grant/Award	Common Stock ^F1	3,840	$0.00	$0.00

Holdings After Transaction: Common Stock — 17,673 shares (Direct)

Footnotes (4)

F1. Represents shares of common stock issuable under a performance-based restricted stock unit award dated June 16, 2025. On October 30, 2026, the performance-based vesting condition was achieved. These shares of common stock vest in two equal installments, assuming continuous service on each vesting date, as follows: October 30, 2026 and October 30, 2027.
F2. The sales reported on this Form 4 represent shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales are mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the reporting person.
F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.28 to $20.27, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.
F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.30 to $20.37, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

Key Figures

Performance-based award shares: 3,840 shares Shares sold: 718 shares Weighted average sale price: $19.6077 per share +4 more

7 metrics

Performance-based award shares 3,840 shares Performance condition achieved October 30, 2026

Shares sold 718 shares November 2, 2026

Weighted average sale price $19.6077 per share 718 shares sold November 2, 2026

Price range for 718-share sale $19.28 to $20.27 per share November 2, 2026

Shares sold 9 shares November 2, 2026

Weighted average sale price $20.3480 per share 9 shares sold November 2, 2026

Price range for 9-share sale $20.30 to $20.37 per share November 2, 2026

Key Terms

restricted stock unit award, sell-to-cover, weighted average price

3 terms

restricted stock unit award financial

"performance-based restricted stock unit award dated June 16, 2025"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

sell-to-cover financial

"funded by a "sell-to-cover" transaction"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ASMB shares did Jeanette M. Bjorkquist sell, and at what prices?

On November 2, 2026, Jeanette M. Bjorkquist sold 718 shares at a weighted average price of $19.6077 (transactions ranged from $19.28 to $20.27) and 9 shares at a weighted average price of $20.3480 (transactions ranged from $20.30 to $20.37). Both sales covered tax withholding under the mandatory sell-to-cover rule and were not discretionary; no Rule 10b5-1 plan is reported.

When do Jeanette M. Bjorkquist’s ASMB restricted stock unit shares vest?

The performance-based vesting condition for the award was achieved October 30, 2026. The 3,840 shares vest in two equal installments, assuming continuous service, on October 30, 2026 and October 30, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bjorkquist Jeanette M

(Last)

(First)

(Middle)

C/O ASSEMBLY BIOSCIENCES, INC.

TWO TOWER PLACE, 7TH FLOOR

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ASSEMBLY BIOSCIENCES, INC. [ ASMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	PFO and PAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/30/2026		A		3,840⁽¹⁾	A	$0	18,400	D
Common Stock	11/02/2026		S⁽²⁾		718	D	$19.6077⁽³⁾	17,682	D
Common Stock	11/02/2026		S⁽²⁾		9	D	$20.348⁽⁴⁾	17,673	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of common stock issuable under a performance-based restricted stock unit award dated June 16, 2025. On October 30, 2026, the performance-based vesting condition was achieved. These shares of common stock vest in two equal installments, assuming continuous service on each vesting date, as follows: October 30, 2026 and October 30, 2027.

2. The sales reported on this Form 4 represent shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales are mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the reporting person.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.28 to $20.27, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.30 to $20.37, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

	/s/ John O. Gunderson, as Attorney-in-Fact	11/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR